A phase I study of rituximab and buparlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma

Leuk Lymphoma. 2022 Jul;63(7):1750-1753. doi: 10.1080/10428194.2022.2034154. Epub 2022 Feb 6.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Letter

MeSH terms

  • Aminopyridines / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Humans
  • Lymphoma, Non-Hodgkin* / diagnosis
  • Lymphoma, Non-Hodgkin* / drug therapy
  • Lymphoma, Non-Hodgkin* / pathology
  • Morpholines / therapeutic use
  • Rituximab / adverse effects

Substances

  • Aminopyridines
  • Morpholines
  • NVP-BKM120
  • Rituximab